Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15	AUG 27	USPATOLD now available on STN
NEWS 16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18	SEP 13	FORIS renamed to SOFIS
NEWS 19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24	OCT 19	BEILSTEIN updated with new compounds

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:41:29 ON 22 OCT 2007

=> file registry
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:42:11 ON 22 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 OCT 2007  HIGHEST RN 951118-42-6
DICTIONARY FILE UPDATES:  19 OCT 2007  HIGHEST RN 951118-42-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10583335\10583335a.str
```





chain nodes :
10 17 18 19 26 27 28 29 31
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 20 21 22 23 24 25
chain bonds :
2-11 4-10 7-28 9-27 13-17 16-26 17-18 17-19 17-20 23-29 26-31
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16 20-21 20-25 21-22 22-23 23-24 24-25
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-10 5-6 5-7 6-9 7-8 7-28 8-9 9-27 13-17 16-26
17-18 17-19 17-20 20-21 20-25 21-22 22-23 23-24 23-29 24-25 26-31
exact bonds :
2-11
normalized bonds :
11-12 11-16 12-13 13-14 14-15 15-16

```
G1:H,Ak,Cb

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:CLASS  18:CLASS  19:CLASS
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  26:CLASS  27:CLASS  28:CLASS
29:CLASS  31:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 13:43:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       89 TO ITERATE

100.0% PROCESSED       89 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1214 TO     2346
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:43:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1639 TO ITERATE

100.0% PROCESSED     1639 ITERATIONS                             25 ANSWERS
SEARCH TIME: 00.00.01

L3           25 SEA SSS FUL L1

=> d scan
```

L3 25 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-[[3-(1-ethyl-4,7-dihydro-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI)
MF C25 H36 N6 O3 S2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L3 25 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI)
MF C24 H34 N6 O3 S2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 25 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI)
MF C23 H32 N6 O3 S2
CI COM

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 25 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(3-methylbutoxy)phenyl]sulfonyl]-4-ethyl- (9CI)
MF C26 H38 N6 O3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.00	173.21

FILE 'CAPLUS' ENTERED AT 13:43:52 ON 22 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Oct 2007 VOL 147 ISS 18
FILE LAST UPDATED: 21 Oct 2007 (20071021/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 4 L3

=> d l4 1-4 ibib abs hitstr

L4 ' ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:570896 CAPLUS
DOCUMENT NUMBER: 143:97390
TITLE: Preparation of pyrazolopyrimidinethione derivatives for treatment of impotence
INVENTOR(S): Li, Shuxin; Ren, Jianping; Zhao, Yanjin; Lv, Qiujun; Guo, Jinhua
PATENT ASSIGNEE(S): The Institute of Radiation Medicine, Academy of Miilitary Medical Sciences Pla, Peop. Rep. China
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058899	A1	20050630	WO 2004-CN1312	20041118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1629163	A	20050622	CN 2003-10118481	20031218
EP 1695976	A1	20060830	EP 2004-797343	20041118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
IN 2006MN00737	A	20070330	IN 2006-MN737	20060623
US 2007219220	A1	20070920	US 2007-583335	20070215
PRIORITY APPLN. INFO.:			CN 2003-10118481 A	20031218
			WO 2004-CN1312 W	20041118

OTHER SOURCE(S): CASREACT 143:97390; MARPAT 143:97390
GI

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. represented by the formula I [wherein R1-R3 = independently ((cyclo)alkoxy)alkyl, alkenyl or aryl; R4 = alkyl, alkenyl, (cyclo)alkoxy, aryl; R5 = H, alkyl, alkenyl, (cyclo)alkoxy, aryl; R6 = H, (cyclo)alkyl, alkenyl, alkylcarbonyl; and pharmaceutically acceptable salts or solvates thereof] were prepared for treatment of impotence. For example, II was given in a multi-step synthesis starting from 4-amino-1-ethyl-3-propylpyrazole-5-carboxamide. I showed enhanced erectile response in rats similar to that of Sildenafil. Thus, I and their pharmaceutical comps. are useful for the treatment of impotence and sexlessness, having high selectivity over PDE V, long action time, less side reactions, and no side effects of blood pressure decreasing and heart rate increasing.

IT 856190-47-1P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidinethione derivs. for treatment of impotence)
RN 856190-47-1 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 856190-48-2P 856190-49-3P 856190-50-6P
856190-51-7P 856190-56-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidinethione derivs. for treatment of impotence)
RN 856190-48-2 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 856190-49-3 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 856190-50-6 CAPLUS
CN Piperazine, 1-[[3-(1-ethyl-4,7-dihydro-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 856190-51-7 CAPLUS
CN Piperazine, 1-[[3-(1-ethyl-4,7-dihydro-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 856190-56-2 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 856190-47-1
CMF C23 H32 N6 O3 S2

Relative stereochemistry.



CM 2

CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:565628 CAPLUS
DOCUMENT NUMBER: 143:211579
TITLE: Low-energy collision-induced dissociation of sildenafil thiono analogues: Gas-phase intramolecular nucleophilic substitution through ion-neutral complexes between a cationic substrate and a thione-containing neutral nucleophile
AUTHOR(S): Lee, Jaeick; Yoo, Hye Hyan; Kang, Min-Yung; Kim, Dong-Hyun
CORPORATE SOURCE: Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology, Seoul, S. Korea
SOURCE: Rapid Communications in Mass Spectrometry (2005), 19(12), 1767-1770
CODEN: RCMSEF; ISSN: 0951-4198
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Collisional-activation mass spectrometry of sildenafil [i.e., 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-(methyl)piperazine] and its thioxo analogs [e.g., 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-(methyl)piperazine] were reported.

IT 479073-72-8 479073-74-0 479073-79-5
479073-80-8 479073-86-4
RL: PRP (Properties)
(study of low energy collision-induced dissociation of sildenafil and its
thioxo analogs and study of gas-phase intramol. nucleophilic substitution through ion-neutral complexes between cationic substrate and thione-containing neutral nucleophile)

RN 479073-72-8 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 479073-74-0 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 479073-79-5 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 479073-80-8 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 479073-86-4 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:524375 CAPLUS
DOCUMENT NUMBER: 141:420374
TITLE: Effects of a new selective phosphodiesterase type 5 inhibitor, KJH-1002, on the relaxation of rabbit corpus cavernosum tissue
AUTHOR(S): Cho, Eun Young; Chung, Sung-Hyun; Kim, Joong Hyup; Kim, Dong-Kyun; Jin, Changbae
CORPORATE SOURCE: Bioanalysis & Biotransformation Research Center, Korea Institute of Science and Technology, Seoul, 130-650, S. Korea
SOURCE: Journal of Applied Pharmacology (2003), 11(4), 232-237
CODEN: JOAPA6; ISSN: 1225-6110
PUBLISHER: Korean Society of Applied Pharmacology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The present study examined functional effects of a new selective phosphodiesterase type 5 inhibitor, 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-thioxo-3-propyl-1H-pyrazolo[4,3]pyrimidin-5-yl)phenylsulfonyl]-4-Me piperazine (KJH-1002), in the isolated rabbit corpus cavernosum (RCC). Relaxing effects of KJH-1002 were also compared with those of sildenafil, which is currently used as an oral therapy for penile erectile dysfunction. In the isolated RCC precontracted with phenylephrine, both KJH-1002 and sildenafil in the concentration range of 1 to 1000 nM, produced a comparable potentiation of the elec. field stimulation-induced relaxation in a concentration-dependent manner. In the sodium nitroprusside (SNP)-induced relaxation, the IC50 values, concns. of SNP required to produce a 50% relaxation of the phenylephrine-induced contraction, were significantly decreased to the similar extent by treatments with KJH-1002 and sildenafil. The results suggest that a new selective phosphodiesterase type 5 inhibitor, KJH-1002, has an augmentative effect on penile erection comparable to that of sildenafil and can be useful for the treatment of erectile dysfunction.

IT 479073-79-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(KJH-1002 phosphodiesterase type-5 inhibitor produced relaxing effect on rabbit corpus cavernosum and showed augmentative effect on penile erection comparable to that of sildenafil and may be useful in erectile dysfunction treatment)

RN 479073-79-5 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:977816 CAPLUS
DOCUMENT NUMBER: 138:55978
TITLE: Preparation of novel pyrazolopyrimidinethiones as phosphodiesterase V inhibitors for treating erectile dysfunction
INVENTOR(S): Kim, Joong-Hyup; Kim, Youseung; Choi, Kyung Il; Kim, Dong Hyun; Nam, Ghilsoo; Seo, Jae Hong
PATENT ASSIGNEE(S): Korea Institute of Science and Technology, S. Korea
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002102802	A1	20021227	WO 2002-KR1126	20020614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2002095286	A	20021226	KR 2001-33382	20010614
AU 2002315822	A1	20030102	AU 2002-315822	20020614
EP 1395593	A1	20040310	EP 2002-741455	20020614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005505509	T	20050224	JP 2003-506275	20020614
US 2004176371	A1	20040909	US 2003-480191	20031209
PRIORITY APPLN. INFO.:			KR 2001-33382 A	20010614
			WO 2002-KR1126 W	20020614

OTHER SOURCE(S): CASREACT 138:55978; MARPAT 138:55978
GI



I

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB The title compds. [I; R1, R2 = H, alkyl, cycloalkyl; R3 = alkyl, cycloalkyl or alkenyl which is unsubstituted or substituted; X = O, NR4; R4 = H, alkyl, cycloalkyl or alkenyl which is unsubstituted or substituted with OH or alkoxy] which exhibit higher inhibitory activities against phosphodiesterase V as well as lower inhibitory activities against phosphodiesterase isoenzymes I, III and VI (biol. data given) and therefore are useful for the treatment of erectile dysfunction, were prepared E.g., a 3-step synthesis of I [R1 = Me; R2 = Pr; R3 = Et; X = NMe], starting from 5-(2-ethoxyphenyl)-1-methyl-3-propyl-1,6-dihydropyrazolo[4,3-d]pyrimidin-7-one, which showed IC50 of 0.59 nM against PDE V, was given.

IT 479073-72-8P 479073-74-0P 479073-76-2P
479073-79-5P 479073-80-8P 479073-82-0P
479073-86-4P 479073-87-5P 479073-88-6P
479073-90-0P 479073-92-2P 479073-93-3P
479073-94-4P 479073-96-6P 479073-97-7P
479073-98-8P 479074-00-5P 479074-01-6P
479074-02-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel pyrazolopyrimidinethiones as PDE5 inhibitors for treating erectile dysfunction)

RN 479073-72-8 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 479073-74-0 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 479073-76-2 CAPLUS
CN 1-Piperazineethanol, 4-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-methoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 479073-79-5 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 479073-80-8 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 479073-82-0 CAPLUS
CN 1-Piperazineethanol, 4-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 479073-86-4 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 479073-87-5 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 479073-88-6 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 479073-90-0 CAPLUS
CN 1-Piperazineethanol, 4-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 479073-92-2 CAPLUS
CN Piperazine, 1-[[4-butoxy-3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 479073-93-3 CAPLUS
CN Piperazine, 1-[[4-butoxy-3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 479073-94-4 CAPLUS
CN 1-Piperazineethanol, 4-[[4-butoxy-3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 479073-96-6 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(2-methylpropoxy)phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 479073-97-7 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(2-methylpropoxy)phenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 479073-98-8 CAPLUS
CN 1-Piperazineethanol, 4-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(2-methylpropoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 479074-00-5 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(3-methylbutoxy)phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 479074-01-6 CAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(3-methylbutoxy)phenyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 479074-02-7 CAPLUS
CN 1-Piperazineethanol, 4-[[3-(4,7-dihydro-1-methyl-3-propyl-7-thioxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(3-methylbutoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log hold
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                          ENTRY    SESSION
FULL ESTIMATED COST                                       27.19     200.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                          ENTRY    SESSION
CA SUBSCRIBER PRICE                                       -3.12      -3.12

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:51:56 ON 22 OCT 2007

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JUL 02  LMEDLINE coverage updated
 NEWS  3  JUL 02  SCISEARCH enhanced with complete author names
 NEWS  4  JUL 02  CHEMCATS accession numbers revised
 NEWS  5  JUL 02  CA/CAplus enhanced with utility model patents from China
 NEWS  6  JUL 16  CAplus enhanced with French and German abstracts
 NEWS  7  JUL 18  CA/CAplus patent coverage enhanced
 NEWS  8  JUL 26  USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS  9  JUL 30  USGENE now available on STN
 NEWS 10  AUG 06  CAS REGISTRY enhanced with new experimental property tags
 NEWS 11  AUG 06  FSTA enhanced with new thesaurus edition
 NEWS 12  AUG 13  CA/CAplus enhanced with additional kind codes for granted
                  patents
 NEWS 13  AUG 20  CA/CAplus enhanced with CAS indexing in pre-1907 records
 NEWS 14  AUG 27  Full-text patent databases enhanced with predefined
                  patent family display formats from INPADOCDB
 NEWS 15  AUG 27  USPATOLD now available on STN
 NEWS 16  AUG 28  CAS REGISTRY enhanced with additional experimental
                  spectral property data
 NEWS 17  SEP 07  STN AnaVist, Version 2.0, now available with Derwent
                  World Patents Index
 NEWS 18  SEP 13  FORIS renamed to SOFIS
 NEWS 19  SEP 13  INPADOCDB enhanced with monthly SDI frequency
 NEWS 20  SEP 17  CA/CAplus enhanced with printed CA page images from
                  1967-1998
 NEWS 21  SEP 17  CAplus coverage extended to include traditional medicine
                  patents
 NEWS 22  SEP 24  EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 23  OCT 02  CA/CAplus enhanced with pre-1907 records from Chemisches
                  Zentralblatt
 NEWS 24  OCT 19  BEILSTEIN updated with new compounds

 NEWS EXPRESS  19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
```